128 related articles for article (PubMed ID: 31285125)
21. Upregulation of microRNA-1 and microRNA-133 contributes to arsenic-induced cardiac electrical remodeling.
Shan H; Zhang Y; Cai B; Chen X; Fan Y; Yang L; Chen X; Liang H; Zhang Y; Song X; Xu C; Lu Y; Yang B; Du Z
Int J Cardiol; 2013 Sep; 167(6):2798-805. PubMed ID: 22889704
[TBL] [Abstract][Full Text] [Related]
22. Biological extraction of realgar by Acidithiobacillus ferrooxidans and its in vitro and in vivo antitumor activities.
Zhang X; Xie QJ; Wang X; Wang B; Li HY
Pharm Biol; 2010 Jan; 48(1):40-7. PubMed ID: 20645754
[TBL] [Abstract][Full Text] [Related]
23. Ellagic acid protects against arsenic trioxide-induced cardiotoxicity in rat.
Hemmati AA; Olapour S; Varzi HN; Khodayar MJ; Dianat M; Mohammadian B; Yaghooti H
Hum Exp Toxicol; 2018 Apr; 37(4):412-419. PubMed ID: 28474970
[TBL] [Abstract][Full Text] [Related]
24. Realgar transforming solution displays anticancer potential against human hepatocellular carcinoma HepG2 cells by inducing ROS.
Song P; Chen P; Wang D; Wu Z; Gao Q; Wang A; Zhu R; Wang Y; Wang X; Zhao L; Duan Z; Zhu S; Cui P; Li Y; Li H
Int J Oncol; 2017 Feb; 50(2):660-670. PubMed ID: 28035418
[TBL] [Abstract][Full Text] [Related]
25. Metallothionein prevention of arsenic trioxide-induced cardiac cell death is associated with its inhibition of mitogen-activated protein kinases activation in vitro and in vivo.
Miao X; Tang Z; Wang Y; Su G; Sun W; Wei W; Li W; Miao L; Cai L; Tan Y; Liu Q
Toxicol Lett; 2013 Jul; 220(3):277-85. PubMed ID: 23664956
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding.
Wu JZ; Ho PC
Eur J Pharm Sci; 2006 Sep; 29(1):35-44. PubMed ID: 16824739
[TBL] [Abstract][Full Text] [Related]
27. The Cardiotoxicity Induced by Arsenic Trioxide is Alleviated by Salvianolic Acid A via Maintaining Calcium Homeostasis and Inhibiting Endoplasmic Reticulum Stress.
Wang R; Zhang J; Wang S; Wang M; Ye T; Du Y; Xie X; Ye J; Sun G; Sun X
Molecules; 2019 Feb; 24(3):. PubMed ID: 30717322
[TBL] [Abstract][Full Text] [Related]
28. [Pharmacokinetics of bacteria bioleaching solution of realgar in rat].
Zhang JH; Fan Q; Li HY
Yao Xue Xue Bao; 2010 Oct; 45(10):1279-84. PubMed ID: 21348306
[TBL] [Abstract][Full Text] [Related]
29. Arsenic-induced interstitial myocardial fibrosis reveals a new insight into drug-induced long QT syndrome.
Chu W; Li C; Qu X; Zhao D; Wang X; Yu X; Cai F; Liang H; Zhang Y; Zhao X; Li B; Qiao G; Dong D; Lu Y; Du Z; Yang B
Cardiovasc Res; 2012 Oct; 96(1):90-8. PubMed ID: 22853924
[TBL] [Abstract][Full Text] [Related]
30. Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide.
Roboz GJ; Ritchie EK; Carlin RF; Samuel M; Gale L; Provenzano-Gober JL; Curcio TJ; Feldman EJ; Kligfield PD
J Clin Oncol; 2014 Nov; 32(33):3723-8. PubMed ID: 25245447
[TBL] [Abstract][Full Text] [Related]
31. L-type calcium current (ICa,L) and inward rectifier potassium current (IK1) are involved in QT prolongation induced by arsenic trioxide in rat.
Chen X; Shan H; Zhao J; Hong Y; Bai Y; Sun I; Pan Z; Zhang Y; Yang B; Du Z
Cell Physiol Biochem; 2010; 26(6):967-74. PubMed ID: 21220927
[TBL] [Abstract][Full Text] [Related]
32. The effect of arsenic trioxide on QT interval prolongation during APL therapy.
Zhou J; Meng R; Li X; Lu C; Fan S; Yang B
Chin Med J (Engl); 2003 Nov; 116(11):1764-6. PubMed ID: 14642155
[TBL] [Abstract][Full Text] [Related]
33. Arsenic in cancer treatment: challenges for application of realgar nanoparticles (a minireview).
Baláž P; Sedlák J
Toxins (Basel); 2010 Jun; 2(6):1568-81. PubMed ID: 22069650
[TBL] [Abstract][Full Text] [Related]
34. Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia.
Torka P; Al Ustwani O; Wetzler M; Wang ES; Griffiths EA
Blood Rev; 2016 May; 30(3):201-11. PubMed ID: 26709030
[TBL] [Abstract][Full Text] [Related]
35. QT prolongation: a case of arsenical pericardial and pleural effusion.
Vizzardi E; Zanini G; Antonioli E; D'Aloia A; Raddino R; Cas LD
Cardiovasc Toxicol; 2008 Mar; 8(1):41-4. PubMed ID: 18084726
[TBL] [Abstract][Full Text] [Related]
36. Mechanism of As2O3-Induced Action Potential Prolongation and Using hiPS-CMs to Evaluate the Rescue Efficacy of Drugs With Different Rescue Mechanism.
Yan M; Feng L; Shi Y; Wang J; Liu Y; Li F; Li B
Toxicol Sci; 2017 Aug; 158(2):379-390. PubMed ID: 28521025
[TBL] [Abstract][Full Text] [Related]
37. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.
Cholujova D; Bujnakova Z; Dutkova E; Hideshima T; Groen RW; Mitsiades CS; Richardson PG; Dorfman DM; Balaz P; Anderson KC; Jakubikova J
Br J Haematol; 2017 Dec; 179(5):756-771. PubMed ID: 29048129
[TBL] [Abstract][Full Text] [Related]
38. Phloretin ameliorates arsenic trioxide induced mitochondrial dysfunction in H9c2 cardiomyoblasts mediated via alterations in membrane permeability and ETC complexes.
Vineetha VP; Soumya RS; Raghu KG
Eur J Pharmacol; 2015 May; 754():162-72. PubMed ID: 25746422
[TBL] [Abstract][Full Text] [Related]
39. Morphine Attenuated the Cytotoxicity Induced by Arsenic Trioxide in H9c2 Cardiomyocytes.
Amini-Khoei H; Hosseini MJ; Momeny M; Rahimi-Balaei M; Amiri S; Haj-Mirzaian A; Khedri M; Jahanabadi S; Mohammadi-Asl A; Mehr SE; Dehpour AR
Biol Trace Elem Res; 2016 Sep; 173(1):132-9. PubMed ID: 26815588
[TBL] [Abstract][Full Text] [Related]
40. Omega-3 Fatty Acid Protects Against Arsenic Trioxide-Induced Cardiotoxicity In Vitro and In Vivo.
Varghese MV; Abhilash M; Paul MV; Alex M; Nair RH
Cardiovasc Toxicol; 2017 Apr; 17(2):109-119. PubMed ID: 26886836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
